These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 19747143)

  • 21. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.
    Bebrone C; Lassaux P; Vercheval L; Sohier JS; Jehaes A; Sauvage E; Galleni M
    Drugs; 2010 Apr; 70(6):651-79. PubMed ID: 20394454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-lactamase inhibitors: agents to overcome bacterial resistance.
    Maiti SN; Phillips OA; Micetich RG; Livermore DM
    Curr Med Chem; 1998 Dec; 5(6):441-56. PubMed ID: 9873109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactamase-mediated resistance and opportunities for its control.
    Livermore DM
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():25-41. PubMed ID: 9688449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.
    Shapiro AB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three decades of beta-lactamase inhibitors.
    Drawz SM; Bonomo RA
    Clin Microbiol Rev; 2010 Jan; 23(1):160-201. PubMed ID: 20065329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria.
    Davies DT; Everett M
    Acc Chem Res; 2021 May; 54(9):2055-2064. PubMed ID: 33788541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
    Concha NO; Janson CA; Rowling P; Pearson S; Cheever CA; Clarke BP; Lewis C; Galleni M; Frère JM; Payne DJ; Bateson JH; Abdel-Meguid SS
    Biochemistry; 2000 Apr; 39(15):4288-98. PubMed ID: 10757977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A close look onto structural models and primary ligands of metallo-β-lactamases.
    Raczynska JE; Shabalin IG; Minor W; Wlodawer A; Jaskolski M
    Drug Resist Updat; 2018 Sep; 40():1-12. PubMed ID: 30466711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [MULTIRESISTANT BACTERIA].
    Bedenić B; Sardelić S; Ladavac M
    Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
    Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
    Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.
    Venkatesan AM; Agarwal A; Abe T; Ushirogochi H; Yamamura I; Kumagai T; Petersen PJ; Weiss WJ; Lenoy E; Yang Y; Shlaes DM; Ryan JL; Mansour TS
    Bioorg Med Chem; 2004 Nov; 12(22):5807-17. PubMed ID: 15498657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B
    Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-lactam antibiotics: An overview from a medicinal chemistry perspective.
    Lima LM; Silva BNMD; Barbosa G; Barreiro EJ
    Eur J Med Chem; 2020 Dec; 208():112829. PubMed ID: 33002736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.
    Georgopapadakou NH
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1307-18. PubMed ID: 15461559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.